3013 SCIENCE PARK, SAN DIEGO, CA
Gossamer Bio, Inc. Amends Certificate of Incorporation for Series A-1 Stock
Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
Announces Second Quarter 2026 Financial Results and Provides Business Update
Earnings Release
Changes in Board, Management or Compensation, Amendments to Articles of Incorporation or Bylaws, Shareholder votes
Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
Reg. FD
Director Re-Elections at Gossamer Bio; Ernst & Young Ratified as Auditor
Q2
Q1
Q3
FY 2024
Effectiveness Notice
S-3ASR
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
RW
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Post-Effective Amendment to Registration Statement
Automatic Shelf Registration Statement
Submission Upload